Martin Shkreli Net Worth

Martin Shkreli Net Worth

Facts of Martin Shkreli Net Worth

Net worth$50 million
Date of Birth:1983 March 17
First NameMartin
Last NameShkreli
NationalityAmerican
Age:36 years old
Birth Nation: United States
Height: 5 Feet 6 Inch

You might have heard about American businessman and hedge fund manager, Martin Shkreli who is also a co-founder and former chief executive officer CEO of the biotechnology firm Retrophin. Now, people are surfing around to find out Martin Shkreli’s net worth, sources of income, and more about him.

Besides Retrophin, he is a former CEO and founder of Turing Pharmaceuticals. He is also co-founder of hedge funds Elea Capital and has now been expected to have a huge amount of net worth. Scroll down:

How much is Martin Shkreli’s Net Worth?

Before directly jumping of to Martin Shkreli’s net worth, let me include some of his highlighted career details.

For your information, Shkreli is a co-founder of the hedge funds MSMB Healthcare, MSMB Capital Management, and Elea Capital. He is also the CEO of the start-up software company “Godel Systems” founded back in August 2016.

And now, Martin Shkreli is one of the youngest businessmen in the world. Martin Shkreli’s net worth is estimated to be around $50 million. But a couple of sources claim that his net worth is over $70 million.

But as of now, he claims that he has no cash left.

While checking the details of Shkreli’s earnings, he was able to gain $6,359,300 through Rretrophin Pharma in 2012. During 2012,c Martin Shkreli’s net worth was estimated to be around $57,142,857. In 2013, he earned around $7,843,137 and made his net worth around $80,000,000.

In the following year, Martin Shkreli earned $10,230,179 with Turing Pharma and his net worth increased up to $86,956,522. His net worth in 2015 was $100,000,000 and earned around $11,764,706.

Martin Shkreli's Drug Price Hike Controversy

In 2015, Shrekli began his journey in Turning Pharmaceuticals where he got FDA approvals and licenses for the major expensive drugs within a couple of months.

There was a huge controversy when Shkreli hiked the price of HIV drug Daraprim in September 2015. He increased the price of the HIV drug from $13.50 to $750 per tablet.

When the price of the HIV drug got extremely high, it causes a lot of problems in the treatment of HIV all over the country. Thousands of HIV patients got affected because of the price hike and even resulted in an irreparable harm to patients.

For the extremely hike of price, Martin Shkreli had to face a huge criticism from the several medical associations and business tie-ups. Later, he had to resign from Turing. After he resigned, board chairman Ron Tilles replaced him.

Furthermore, the record label Collect Records responded to the controversy by publicly ending its business relationship with him, who invested in the company.

In an interview with Bloomberg Markets in September 2015, he explained that although the price increased, patient co-pays would actually be lower which means that the drug can be at no cost. Turing had expanded the free drug program where the drug was sold at its half price, costing $1.

Though Martin Shkreli has gone over all those controversies, he still is active in the field, and his net worth will definitely go high in coming days.


AmericanBusinessmanMartin ShkreliHedge Fund ManagerCEO of RetrophinPharmaceuticals